Tokyo and Gaithersburg -— Hitachi High-Technologies Corporation

and OpGen, Inc., a leading genetic analysis company, today announced the introduction of an

Early Access Program for its upcoming Human Chromosome ExplorerSM, human chromosome

mapping analytical service for clinical research and life science research applications.

The companies entered a development agreement in October 2013 to develop the human

chromosome mapping analytical service. The service combines OpGen’s market-leading

Whole Genome Mapping™ technology with a newly developed suite of bioinformatics and data

management applications in Hitachi High-Technologies’ and Hitachi group’s cloud-based

environment for comprehensive and efficient, automated analysis of structural variations of

entire human genomes.

Collaborations under the early access program are currently underway. Hitachi

High-Technologies is accepting additional applications for human structural variation projects

under the early access program through the end of the year, and expects to launch the full

analytical service including automated detection and analysis of heterozygous chromosomal

aberrations in early 2015.

“We are pleased to be collaborating with the Hitachi High-Technologies and OpGen teams to

explore the capabilities of their technology to complement massively parallel sequencing

approaches to the detection of complex structural variations in humans. We are especially

intrigued with the human chromosome mapping technology and its potential to resolve variation in

complex genomic regions that are not accessible to short-read sequencing,” said Michael

Talkowski, Assistant Professor of Neurology, Psychiatry, and Pathology, and Director, Genomics

and Technology Core at Massachusetts General Hospital, Harvard Medical School.The Human Chromosome ExplorerSM service enables customers to have high resolution, high

fidelity whole genome maps produced for human samples, complete with automated,

comprehensive reports of structural variations across the human genome, with secure data access

and analysis in the cloud. The complete cloud solution further enables customers to store,

analyze, and manage their human genome SV datasets and projects and to share data through

collaboration modules, genome annotation database interfaces, and other informatics tools.

“We are very enthusiastic about our ongoing partnership with Hitachi High-Technologies and the

deepening relationship between our two companies”, said Evan Jones, Chairman and CEO of

OpGen. “The joint development of the new human chromosome mapping and structural

variation analytical platform is a great example of a solutions approach to human genome

informatics that will ultimately advance translational research and the study of numerous human

genetic diseases. We look forward to continued work with our Hitachi High-Technologies

colleagues as we add features and deploy this enabling platform service on a global basis.”

The global, yet information-rich view from Whole Genome MappingTM

offers critical insight

into the order, orientation, length, and location of biologically and clinically significant

components of complex genomes, which may include DNA copy number variations, indels,

inversions, and translocations—genetic information which is often undetected with next

generation sequencing alone. These genetic variations have been associated with cancer,

autism, neuropsychiatric disorders, and many cognitive and developmental disorders.

“We believe the Human Chromosome ExplorerSM will be a highly complementary technology

for whole genome analysis with next generation sequencing technologies, for the analysis of

long-range genetic events. We are excited to provide enhanced value for the discovery of

complex structural variants in human chromosomes with our developing technology with

OpGen,” said Yoshito Nejime, Deputy General Manager, New Business Development Division

of Hitachi High-Technologies Corporation.

Hitachi High-Technologies and OpGen plan to introduce more details about the service in the

booth 839 at the American Society of Human Genetics Annual Meeting, being held October

18-22 in San Diego.

About Hitachi High-Technologies Corporation

Hitachi High-Technologies Corporation (TOKYO:8036), headquartered in Tokyo, Japan, is

engaged in activities in a broad range of fields, including Electronic Device Systems, Fine

Technology Systems, Science & Medical Systems, Industrial & IT Systems, and Advanced Industrial Products. The company’s consolidated sales for FY 2013 were more than $6.2 billion.

For further information, visit https://www.hitachi-hitec.com/global/.

About OpGen, Inc.

OpGen is a commercial-stage company using rapid molecular testing and bioinformatics to

combat multi-drug resistant infections. Our products and services enable healthcare providers

to rapidly identify hospital patients who are colonized with life threatening, multi-drug resistant

organisms (MDROs). The Acuitas™ MDRO Gene Test provides a comprehensive profile of

MDRO resistance genes from patients screened for colonization or infection. Our products are

enabled by our Lighthouse™ MDRO Management Solution which provides detailed molecular

information about an individual patient’s resistance profile and integrates this information with

data from other patients and hospital wide aggregate results to help improve overall patient

outcomes and to reduce hospital costs.

We have developed and commercialized the Argus® Whole Genome Mapping™ System,

MapIt™ Services, and MapSolver™ bioinformatics products and services for mapping and

analysis of microbial, plant, animal, and human genomes. Through our strategic

partnership with Hitachi High-Technologies we are commercializing Human Chromosome

ExplorerSM, a complete solution for mapping, assembly, and analysis of human genomes

with high performance bioinformatics. For more information, please visit

www.opgen.com.